Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response.

Détails

Ressource 1Télécharger: BIB_0768C7F7DFC1.P001.pdf (3679.40 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_0768C7F7DFC1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response.
Périodique
Proceedings of the National Academy of Sciences of the United States of America
Auteur⸱e⸱s
Brettmann E.A., Shaik J.S., Zangger H., Lye L.F., Kuhlmann F.M., Akopyants N.S., Oschwald D.M., Owens K.L., Hickerson S.M., Ronet C., Fasel N., Beverley S.M.
ISSN
1091-6490 (Electronic)
ISSN-L
0027-8424
Statut éditorial
Publié
Date de publication
25/10/2016
Peer-reviewed
Oui
Volume
113
Numéro
43
Pages
11998-12005
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural
Publication Status: ppublish
Résumé
Many Leishmania (Viannia) parasites harbor the double-stranded RNA virus Leishmania RNA virus 1 (LRV1), which has been associated with increased disease severity in animal models and humans and with drug treatment failures in humans. Remarkably, LRV1 survives in the presence of an active RNAi pathway, which in many organisms controls RNA viruses. We found significant levels (0.4 to 2.5%) of small RNAs derived from LRV1 in both Leishmania braziliensis and Leishmania guyanensis, mapping across both strands and with properties consistent with Dicer-mediated cleavage of the dsRNA genome. LRV1 lacks cis- or trans-acting RNAi inhibitory activities, suggesting that virus retention must be maintained by a balance between RNAi activity and LRV1 replication. To tilt this balance toward elimination, we targeted LRV1 using long-hairpin/stem-loop constructs similar to those effective against chromosomal genes. LRV1 was completely eliminated, at high efficiency, accompanied by a massive overproduction of LRV1-specific siRNAs, representing as much as 87% of the total. For both L. braziliensis and L. guyanensis, RNAi-derived LRV1-negative lines were no longer able to induce a Toll-like receptor 3-dependent hyperinflammatory cytokine response in infected macrophages. We demonstrate in vitro a role for LRV1 in virulence of L. braziliensis, the Leishmania species responsible for the vast majority of mucocutaneous leishmaniasis cases. These findings establish a targeted method for elimination of LRV1, and potentially of other Leishmania viruses, which will facilitate mechanistic dissection of the role of LRV1-mediated virulence. Moreover, our data establish a third paradigm for RNAi-viral relationships in evolution: one of balance rather than elimination.

Mots-clé
Animals, Antiprotozoal Agents/chemistry, Antiprotozoal Agents/metabolism, Antiprotozoal Agents/pharmacology, Gene Expression, Inverted Repeat Sequences, Leishmania braziliensis/pathogenicity, Leishmania braziliensis/virology, Leishmania guyanensis/pathogenicity, Leishmania guyanensis/virology, Leishmaniasis, Mucocutaneous/drug therapy, Leishmaniasis, Mucocutaneous/parasitology, Leishmaniasis, Mucocutaneous/virology, Leishmaniavirus/drug effects, Leishmaniavirus/genetics, Leishmaniavirus/metabolism, Macrophages/parasitology, Macrophages/virology, Mice, Oligoribonucleotides, Antisense/genetics, Oligoribonucleotides, Antisense/metabolism, Oligoribonucleotides, Antisense/pharmacology, RNA Interference/drug effects, RNA, Double-Stranded/antagonists & inhibitors, RNA, Double-Stranded/genetics, RNA, Double-Stranded/metabolism, RNA, Viral/antagonists & inhibitors, RNA, Viral/genetics, RNA, Viral/metabolism, Symbiosis/genetics, Toll-Like Receptor 3/genetics, Toll-Like Receptor 3/metabolism, Virus Replication/drug effects, dsRNA virus, endosymbiont, microbial pathogenesis, protozoan parasite, trypanosomatid protozoa
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/10/2016 10:16
Dernière modification de la notice
20/08/2019 12:29
Données d'usage